-+ 0.00%
-+ 0.00%
-+ 0.00%

Annexin expands NEXUS trial to allow anti-VEGF loading dose before vanexin in RVO patients

PUBT·08/21/2026 06:05:15
Listen to the news
Annexin expands NEXUS trial to allow anti-VEGF loading dose before vanexin in RVO patients
  • Annexin Pharmaceuticals broadened its NEXUS retinal vein occlusion study to include patients who received a single anti-VEGF injection.
  • Results have not been presented; the change is based on interim safety, tolerability, and early effect signals seen so far.
  • The strategy pairs rapid swelling control from anti-VEGF with vanexin dosing aimed at longer-term vision maintenance, potentially reducing repeat injections.
  • Germany’s BfArM cleared the updated protocol; UK MHRA review is pending.
  • An initial three-patient cohort is planned to support a Phase 2b design and inform partnering discussions.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Annexin Pharmaceuticals AB (publ) published the original content used to generate this news brief on August 21, 2026, and is solely responsible for the information contained therein.